Analyst Price Target Update on ZIOPHARM Oncology Inc (NASDAQ:ZIOP)

ZIOPHARM Oncology Inc (NASDAQ:ZIOP) stock has received a short term price target of $ 14 from 2 Analyst. The share price can be expected to fluctuate from the mean short term target, can be seen from the standard deviation reading of $9.9. The higher estimate of target price is $21 , while the lower price target estimate is $7

Many analysts have stated their opinion on the company shares. Raymond James initiates coverage on ZIOPHARM Oncology Inc (NASDAQ:ZIOP). According to the latest information available, the shares are now rated Market Perform by the analysts at the agency. The rating by the firm was issued on June 2, 2016. Company shares have received an average consensus rating of Hold for the current week

On the companys insider trading activities, The Securities and Exchange Commission has divulged that Belbel Caesar J, officer (COO, CLO, and Secretary) of Ziopharm Oncology Inc, had unloaded 153,333 shares at an average price of $12.84 in a transaction dated on November 19, 2015. The total value of the transaction was worth $1,968,796.

ZIOPHARM Oncology Inc (NASDAQ:ZIOP) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.16 points or 2.47% at $6.31 with 1,544,510 shares getting traded. Post opening the session at $6.34, the shares hit an intraday low of $6.275 and an intraday high of $6.69 and the price was in this range throughout the day. The company has a market cap of $832 million and the number of outstanding shares have been calculated to be 131,840,428 shares. The 52-week high of ZIOPHARM Oncology Inc (NASDAQ:ZIOP) is $14.93 and the 52-week low is $4.56.

ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is engaged in the acquisition, development and commercialization of a portfolio of cancer therapies through synthetic biology. The Companys pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies. The Companys clinical stage product candidate, Ad-RTS-IL-12 is used with the oral activator veledimex being developed for the treatment of oncology. Ad-RTS-IL-12 in combination with veledimex uses the synthetic biology platform (gene-delivery system) to produce Interleukin-12, or IL-12, a potent, naturally occurring anti-cancer protein. The Company has completed two Phase II studies evaluating Ad-RTS-IL-12 in combination with veledimex, for the treatment of metastatic melanoma, and for the treatment of metastatic breast cancer. The Company is also developing CAR-T Cells (Cytokine products).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *